These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 11591605)

  • 1. Report from the 93rd Cardiovascular and Renal Drugs Advisory Committee Meeting, August 9-10, 2001.
    Fleming T; Lindenfeld J; Lipicky R; Armstrong P
    Circulation; 2001 Oct; 104(15):1742. PubMed ID: 11591605
    [No Abstract]   [Full Text] [Related]  

  • 2. Report From the 93rd Cardiovascular and Renal Drugs Advisory Committee Meeting, August 9-10, 2001.
    SoRelle R
    Circulation; 2001 Aug; 104(9):E9017-8. PubMed ID: 11526948
    [No Abstract]   [Full Text] [Related]  

  • 3. Drug therapy for pulmonary arterial hypertension: what's on the menu today?
    Mehta S
    Chest; 2003 Dec; 124(6):2045-9. PubMed ID: 14665473
    [No Abstract]   [Full Text] [Related]  

  • 4. Disproportionate pulmonary hypertension in a patient with early-onset pulmonary emphysema treated with specific drugs for pulmonary arterial hypertension.
    Shimizu M; Imanishi J; Takano T; Miwa Y
    Intern Med; 2011; 50(20):2341-6. PubMed ID: 22001462
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A new era in the treatment of primary pulmonary hypertension.
    Bailey CL; Channick RN; Rubin LJ
    Heart; 2001 Mar; 85(3):251-2. PubMed ID: 11179256
    [No Abstract]   [Full Text] [Related]  

  • 6. Bosentan treatment in patients with primary pulmonary hypertension receiving nonparenteral prostanoids.
    Hoeper MM; Taha N; Bekjarova A; Gatzke R; Spiekerkoetter E
    Eur Respir J; 2003 Aug; 22(2):330-4. PubMed ID: 12952269
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bosentan and sildenafil: should the combination therapy be a valid alternative in childhood to prostacyclin infusion?
    Brancaccio G; Toscano A; Bevilacqua M; Di Chiara L; Parisi F
    Pediatr Transplant; 2007 Feb; 11(1):110-2. PubMed ID: 17239133
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical and cost-effectiveness of epoprostenol, iloprost, bosentan, sitaxentan and sildenafil for pulmonary arterial hypertension within their licensed indications: a systematic review and economic evaluation.
    Chen YF; Jowett S; Barton P; Malottki K; Hyde C; Gibbs JS; Pepke-Zaba J; Fry-Smith A; Roberts J; Moore D
    Health Technol Assess; 2009 Oct; 13(49):1-320. PubMed ID: 19863849
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Pulmonary hypertension].
    Kovacs G; Olschewski H
    Dtsch Med Wochenschr; 2012 Oct; 137(40):2026-8. PubMed ID: 23023615
    [No Abstract]   [Full Text] [Related]  

  • 10. New answers raise new questions in pulmonary arterial hypertension.
    Kawut SM; Palevsky HI
    Eur Respir J; 2004 Jun; 23(6):799-801. PubMed ID: 15218988
    [No Abstract]   [Full Text] [Related]  

  • 11. Bosentan.
    Chin K; Channick R
    Expert Rev Cardiovasc Ther; 2004 Mar; 2(2):175-82. PubMed ID: 15151466
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bosentan improves exercise tolerance and Tei index in patients with pulmonary hypertension and prostanoid therapy.
    Seyfarth HJ; Pankau H; Hammerschmidt S; Schauer J; Wirtz H; Winkler J
    Chest; 2005 Aug; 128(2):709-13. PubMed ID: 16100158
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bosentan for pulmonary arterial hypertension.
    Drug Ther Bull; 2003 Sep; 41(9):70-2. PubMed ID: 14531210
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The status of pulmonary arterial hypertension in 2008.
    Farber HW
    Circulation; 2008 Jun; 117(23):2966-8. PubMed ID: 18541751
    [No Abstract]   [Full Text] [Related]  

  • 15. Treatment of pulmonary arterial hypertension: a preliminary decision analysis.
    Highland KB; Strange C; Mazur J; Simpson KN
    Chest; 2003 Dec; 124(6):2087-92. PubMed ID: 14665484
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2.
    Humbert M; Barst RJ; Robbins IM; Channick RN; Galiè N; Boonstra A; Rubin LJ; Horn EM; Manes A; Simonneau G
    Eur Respir J; 2004 Sep; 24(3):353-9. PubMed ID: 15358690
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Bosentan in pulmonary hypertension].
    Heinzl S
    Med Monatsschr Pharm; 2002 Mar; 25(3):74-6. PubMed ID: 11925765
    [No Abstract]   [Full Text] [Related]  

  • 18. Conversion to bosentan from prostacyclin infusion therapy in pulmonary arterial hypertension: a pilot study.
    Steiner MK; Preston IR; Klinger JR; Criner GJ; Waxman AB; Farber HW; Hill NS
    Chest; 2006 Nov; 130(5):1471-80. PubMed ID: 17099026
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Successful epoprostenol withdrawal in pulmonary arterial hypertension: case report and literature review.
    Demerouti EA; Manginas AN; Athanassopoulos GD; Karatasakis GT; Leontiadis ED; Pavlides GS
    Respir Care; 2013 Feb; 58(2):e1-5. PubMed ID: 22710078
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of pulmonary arterial hypertension: a step forward.
    Sharma S
    Chest; 2003 Jul; 124(1):8-11. PubMed ID: 12853493
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.